Structural identification of recombinant human CD83 mutant variant as a potent therapeutic protein.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Protein Expression and Purification

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.pep.2010.05.016PMID 20566323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein.

  2009cited by this paper
• CD83: an update on functions and prospects of the maturation marker of dendritic cells

  2007cited by this paper
• Determination of the inhibitory activity and biological half-live of soluble CD83: comparison of wild type and mutant isoforms.

  2006cited by this paper
• CD83 is a dimer: Comparative analysis of monomeric and dimeric isoforms.

  2005cited by this paper
• Prevention and Treatment of Experimental Autoimmune Encephalomyelitis by Soluble CD83

  2004cited by this paper
• Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies.

  2002cited by this paper
• The Extracellular Domain of CD83 Inhibits Dendritic Cell–mediated T Cell Stimulation and Binds to a Ligand on Dendritic Cells

  2001cited by this paper
• Inhibition of Cd83 Cell Surface Expression during Dendritic Cell Maturation by Interference with Nuclear Export of Cd83 mRNA

  2000cited by this paper
• Disulfide bonds and protein folding.

  2000cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Protein structure : a practical approach

  1997cited by this paper
• Probing protein folding and stability using disulfide bonds

  1997cited by this paper
• Preparation and storage of competent Escherichia coli cells.

  1993cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper

• The fungal‐resistance factors BmSPI38 and BmSPI39 predominantly exist as tetramers, not monomers, in Bombyx mori

  2018cites this paper
• Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes

  2017cites this paper
• Binding to the TLR 4 / MD2 Complex on Soluble CD 83 Inhibits T Cell Activation by

  2017cites this paper
• Crystal Structure of the Extracellular Domain of the Human Dendritic Cell Surface Marker CD83.

  2017cites this paper
• Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system.

  2011cites this paper
• Production of Recombinant Human Soluble CD 83 in an Eukaryotic System and Generation of Tissue-Specific CD 83 Knock-out Mice

  2011cites this paper
• Molecular manipulation associated with disulfide bond formation to enhance the stability of recombinant therapeutic protein.

  2011cites this paper
• Effects of disulfide bond formation in production of the recombinant extracellular domain of human CD83 as a therapeutic protein

  2010cites this paper